ContextVision’s third quarter sees a recovery in sales and market entry in digital pathology is on track
STOCKHOLM – Oct 22, 2020 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its third quarter.
“We are making progress according to plan in digital pathology, and with several completed installations we can now proceed with extended studies in the clinical workflow. The pandemic situation continues to keep business somewhat unpredictable. However, sales in our medical imaging business have increased compared to the second quarter, allowing us to be cautiously optimistic, and our total YTD sales growth as of Sep 30th is greater than that of the same period in 2019. While we see minor short-term effects on sales, and travel restrictions slowing down new business, our strategy is to continue developing the company brick by brick while keeping our financials under control. What is most important is that these effects are temporary; the present situation only emphasizes the need for efficient digital solutions within healthcare,” says Fredrik Palm, CEO of ContextVision.
INIFY® Prostate Screening, the company’s first decision support tool for prostate cancer diagnosis, was granted CE -mark status in June, which means that it is now available for clinical use within EU. The predicting engine in the software is built on deep learning algorithms, offering superior accuracy on a pixel level. The product will allow pathologists to focus their time on specimens with suspicious cancer and minimize time spent on benign tissue.
Several installations at key reference centers have been completed in the third quarter, in order to broaden use and perform extended studies in the clinical workflow. Advanced discussions are in progress with additional pathology laboratories in the digital forefront. In parallel, we continue our R&D activities, with this next-generation product for prostate cancer, as well as other cancer types that are known to cause the heaviest burden on the pathology labs around the world.
Several new agreements, as well as a regional extension with an existing strategic customer, have been signed during the quarter. One contract includes Rivent®, our latest product for 2D ultrasound released in May this year. These achievements have been successfully carried out solely via remote communication.
Sales in Q3 ended at 22 MSEK, which is on par with sales in Q3 2019 after adjusting for currency effects, and a 9% increase compared to this year’s previous quarter. EBITDA was 4.9 MSEK, and the operating result ended at 1.2 MSEK. X-ray business continues on positive path, growing by 18% compared to the corresponding quarter 2019, while 2D ultrasound remains at a slightly lower level due to other acute priorities among hospitals and clinics.
Sales for the first nine months of the fiscal year grew 6% compared to the same period in 2019, and ended at 71.2 MSEK, with an EBITDA of 22.5 MSEK.
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.
Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.
The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.
For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
JSC Olainfarm & Adalvo to launch a new urology product in 17 countries in 2022-202316.6.2021 08:05:00 CEST | Press release
Following the five-year strategy and developing one of the main therapeutic areas, JSC Olainfarm and Adalvo have signed a licensing and supply agreement to launch a new product in the urology segment which is targeted to be the 1st to market opportunity in all of these markets. The prescription product will help millions of patients in 17 different countries to regain ease and quality of life. In partnership Olainfarm will manage product regulatory affairs, distribution and promotion in Latvia, Russia, Kazakhstan, Belarus, Ukraine, and other countries of current presence and Adalvo will be responsible for development, manufacturing and will support Olainfarm for its market access activities in all the markets. Currently, Olainfarm has established a sustainable business model in the EU and CIS countries with more than 300 medical and marketing professionals. Full commercialization of this prescription product is expected to be in 2022-2023. “We are very pleased to be in this partnership
Brains Bioceutical Corp. completes a USD $31.9 Million Capital Raise with Lead Investor DSM Venturing16.6.2021 08:00:00 CEST | Press release
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp. (“Brains” or the “Company”) is pleased to announce the completion of a USD $31.9 million capital raise with DSM Venturing and existing Brains shareholders. DSM Venturing, who acted as lead investor in this round, is the corporate venture arm of Royal DSM (“DSM”), a global, purpose led science-based company active in health, nutrition and sustainable living. This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Del Morgan & Co. acted as Brains’ financial agent in respect to the capital raise. “The completion of the capital raise marks an exciting milestone for the Brains’ team. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains' CEO & Chairman Rick Brar. “The growing demand for isolated CBD Active Pharmaceutical In
ForFarmers N.V.: Adrie van der Ven to leave ForFarmers16.6.2021 06:55:00 CEST | Press release
Lochem, 16 June 2021 Adrie van der Ven to leave ForFarmers Adrie van der Ven will leave ForFarmers as of 1 January 2022. This has been decided in mutual understanding. Van der Ven will remain COO and member of the Executive Board until 1 October 2021 and will subsequently stay on as advisor until the end of the year. This will allow a smooth transition of his tasks and responsibilities in the coming period. Yoram Knoop, CEO of ForFarmers: “Adrie joined the Executive Board in 2019. He has made a significant contribution to the realisation of the strategy Build to Grow 2025, for which I am grateful to him. In addition, the important step to the growth market Poland was made under his leadership. On behalf of myself and my colleagues I want to wish him the best for the future.” The Executive Board, in consultation with the Supervisory Board, will announce how the succession of Adrie van der Ven will be dealt with later. This press release contains information that qualifies as inside info
LeddarTech Congratulates the MILLA Group’s Debut of Their Autonomous POD Equipped With the Leddar Pixell at Two Major June Events, Including the French Grand Prix 2021 F1 Race16.6.2021 06:12:00 CEST | Press release
QUEBEC CITY, June 16, 2021 (GLOBE NEWSWIRE) -- LeddarTech®, a global leader in Level 1-5 ADAS and AD sensing technology, is pleased to announce that its customer, France-based MILLA Group, has selected LeddarTech sensing solutions as a critical contributor to the autonomous enablement of the MILLA POD. MILLA has adopted LeddarTech’s award-winning 3D solid-state LiDAR, Leddar™ Pixell, for its 180-degree field of view and highly reliable object detection capabilities. The MILLA Group, located in France, develops and markets an autonomous electric shuttle. MILLA is a leader in mobility and an essential resource for all public and private organizations wishing to implement an adapted, efficient, and sustainable mobility solution. MILLA will feature their fully autonomous electric POD vehicles, equipped with the Leddar Pixell, at two major June events in France. June 16-19 VIVA Technology Conference in Paris, France MILLA will showcase its fully autonomous POD shuttle at the world-renowned
NEP Joins Host City Americas as Event Delivery Partner15.6.2021 23:15:39 CEST | Press release
PITTSBURGH, Pa. (USA), June 15, 2021 (GLOBE NEWSWIRE) -- NEP Group, the world’s leading technical production partner for premier content producers of live sports and entertainment, is proud to support the Host City Americas Digital Conference, June 29th through 30th. This event will welcome 1000+ participants including, IOC Members, Sports Ministers, Mayors, International Federations and Organizing Committee leaders to showcase the opportunities ahead as we emerge from the pandemic to a landscape defined by digitalization and private investment. As official Event Delivery Partner, NEP’s robust live virtual event and online conferencing platform, developed by the Creative Technology division of NEP, will power the event, providing two days of insightful sessions on the main stage, plus opportunities for delegates to ask questions and chat about main stage content. Networking opportunities will also be available for delegates to meet with each other throughout the event. NEP CEO Brian Su
Sinch launches new solutions for brands on WhatsApp15.6.2021 18:30:00 CEST | Press release
Businesses can now share additional information and create two-way customer conversations on the world’s most popular messaging platform STOCKHOLM and ATLANTA – June 15, 2021 – Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced that brands can now use the Sinch Conversation API to share additional information, such as back-in-stock updates, product recommendations, and more with opted-in WhatsApp users in applicable regions. WhatsApp, the messaging platform used by 2 billion people worldwide, recently said how it is improving the way businesses can communicate with their customers and will support more types of messages people opt-in to receive, which will make it easier to follow up with customers outside of a 24-hour window. But developing, integrating and orchestrating conversation interactions, can be challenging and complex for businesses. With Sinch’s longstanding WhatsApp business API expertise combined with its powerful Conv
Kallelse till extra bolagsstämma i Klövern AB (publ)15.6.2021 18:00:00 CEST | Pressemelding
Aktieägarna i Klövern AB (publ), org.nr 556482-5833, kallas härmed till extra bolagsstämma fredagen den 9 juli 2021. Mot bakgrund av den pågående pandemin och med hänsyn till myndigheternas föreskrifter och råd om begränsningar av sammankomster för att minska risken för smittspridning genomförs bolagsstämman enbart genom poströstning med stöd av tillfälliga lagregler. Någon stämma med möjlighet att närvara personligen eller genom ombud kommer inte att äga rum. Klövern välkomnar alla aktieägare att utnyttja sin rösträtt vid stämman genom poströstning i den ordning som beskrivs nedan. Information om de vid stämman fattade besluten offentliggörs fredagen den 9 juli 2021 så snart utfallet av poströstningen är slutligt sammanställt. Anmälan m.m. Rätt att delta i stämman genom poströstning har den som dels är införd som aktieägare i den av Euroclear Sweden AB förda aktieboken torsdagen den 1 juli 2021; dels har anmält sitt deltagande genom att ha avgett sin poströst enligt anvisningarna unde